TY - JOUR
T1 - Usefulness of sparfloxacin against Chlamydia pneumoniae infection in patients with bronchial asthma
AU - Horiguchi, T.
AU - Miyazaki, J.
AU - Ohira, D.
AU - Watanabe, Y.
AU - Hayashi, N.
AU - Kobayashi, K.
AU - Torigoe, T.
AU - Fukumoto, K.
AU - Ito, T.
AU - Hirose, M.
AU - Sasaki, Y.
AU - Shiga, M.
AU - Kondo, R.
AU - Handa, M.
AU - Tachikawa, S.
PY - 2005
Y1 - 2005
N2 - The efficacy of sparfloxacin (SPFX) for the control of bronchial asthma was evaluated in 26 patients with suspected Chlamydia pneumoniae infection. Patients were randomly allocated to receive SPFX 200 mg/day (n = 14) or control treatment (n = 12) for 21 days. Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. SPFX-treated patients also had a significantly reduced frequency of asthma symptoms, reduced inhalant β2-stimulant use, and significant increases in morning peak expiratory flow. At the end of the study, C. pneumoniae was undetectable in two SPFX-treated patients who underwent polymerase chain reaction testing, but one control patient who was tested still had detectable levels of C. pneumoniae. These results suggest that SPFX could be used to control bronchial asthma in patients with suspected persistent C. pneumoniae infection.
AB - The efficacy of sparfloxacin (SPFX) for the control of bronchial asthma was evaluated in 26 patients with suspected Chlamydia pneumoniae infection. Patients were randomly allocated to receive SPFX 200 mg/day (n = 14) or control treatment (n = 12) for 21 days. Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. SPFX-treated patients also had a significantly reduced frequency of asthma symptoms, reduced inhalant β2-stimulant use, and significant increases in morning peak expiratory flow. At the end of the study, C. pneumoniae was undetectable in two SPFX-treated patients who underwent polymerase chain reaction testing, but one control patient who was tested still had detectable levels of C. pneumoniae. These results suggest that SPFX could be used to control bronchial asthma in patients with suspected persistent C. pneumoniae infection.
UR - http://www.scopus.com/inward/record.url?scp=29444450275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29444450275&partnerID=8YFLogxK
U2 - 10.1177/147323000503300609
DO - 10.1177/147323000503300609
M3 - Article
C2 - 16372585
AN - SCOPUS:29444450275
VL - 33
SP - 668
EP - 676
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 0300-0605
IS - 6
ER -